Bioventus Inc.
BVS
$8.53
$0.020.18%
NASDAQ
| 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Net Income | 218.05% | 3,902.84% | 161.08% | 129.04% | 46.07% |
| Total Depreciation and Amortization | -5.56% | 22.18% | -7.10% | -7.95% | 0.68% |
| Total Amortization of Deferred Charges | -- | -34.89% | -- | -- | -- |
| Total Other Non-Cash Items | 81.34% | -20.03% | 32.72% | -73.20% | 42.27% |
| Change in Net Operating Assets | 67.39% | 394.45% | 2,431.22% | -91.39% | -111.43% |
| Cash from Operations | 146.22% | 96.50% | 191.76% | 71.07% | -221.92% |
| Capital Expenditure | 30.51% | -1.05% | -639.06% | -787.01% | -183.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 30.51% | -102.41% | -639.06% | -1,677.92% | 17.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -340.00% | 40.43% | -- | 39.50% | -63.61% |
| Issuance of Common Stock | -20.00% | -53.67% | -82.64% | 116.26% | -15.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 97.61% | -104.83% | -34,805.24% | -5,678.95% | -575.20% |
| Cash from Financing | -2,543.93% | 33.62% | -5,618.51% | -86.91% | 122.32% |
| Foreign Exchange rate Adjustments | -241.40% | 106.45% | -184.55% | 148.21% | 179.04% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.04% | 708.18% | -16.48% | 48.19% | -59.27% |